All lobbying filings

Innovative Federal Strategies, LLC

Innovative Federal Strategies, LLC filed a Q2 report for Acurx Pharmaceuticals, Inc. on July 18, 2025, reporting $30,000 in lobbying income.

Lobbying for Acurx Pharmaceuticals, Inc. · biopharmaceutical company

As filed: INNOVATIVE FEDERAL STRATEGIES, LLC for ACURX PHARMACEUTICALS, INC.

All filings by Innovative Federal Strategies, LLC · Everything Acurx Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$30,000

What the client paid this registrant for the period.

Client based in

New York

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Budget/Appropriations

H.R.4026/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Defense

H.R.____/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Bills named in this filing 2

H.R. 4026
POST Act of 2025
S. 2296
National Defense Authorization Act for Fiscal Year 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.